{"id":45919,"date":"2025-11-05T22:36:14","date_gmt":"2025-11-05T14:36:14","guid":{"rendered":"https:\/\/flcube.com\/?p=45919"},"modified":"2025-11-05T22:36:16","modified_gmt":"2025-11-05T14:36:16","slug":"jiangsu-hengrui-secures-priority-review-for-hrs%e2%80%915965-in-chinas-rare%e2%80%91disease-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45919","title":{"rendered":"Jiangsu Hengrui Secures Priority Review for HRS\u20115965 in China\u2019s Rare\u2011Disease Portfolio"},"content":{"rendered":"\n<p>Jiangsu Hengrui Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>Priority Review status<\/strong> to its investigational <strong>HRS\u20115965<\/strong> capsule, targeting adult patients with <strong>paroxysmal nocturnal hemoglobinuria (PNH)<\/strong> who have not yet received complement\u2011inhibitor therapy.<br>The decision positions HRS\u20115965 as a potential first\u2011in\u2011class complement factor\u202fB inhibitor in the rapidly evolving PNH market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-profile\">Therapeutic Profile<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mechanism-of-action\">Mechanism of Action<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HRS\u20115965<\/strong> is a selective <strong>complement factor\u202fB inhibitor<\/strong> that dampens the assembly of the membrane\u2011attack complex (MAC), thereby <strong>reducing both intravascular and extravascular hemolysis<\/strong>.<\/li>\n\n\n\n<li>In pre\u2011clinical and early\u2011phase trials, the molecule has shown the capacity to <strong>elevate hemoglobin concentrations<\/strong> and alleviate anemia in PNH patients who lack prior exposure to complement inhibitors.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The only therapy worldwide with a similar target is Novartis\u2019 <strong>iptacopan hydrochloride capsules (Fabhalta)<\/strong>, approved <em>outside<\/em> of China.<\/li>\n\n\n\n<li>No complement\u2011factor\u202fB inhibitor has yet received approval for PNH in China, giving HRS\u20115965 a distinctive competitive edge pending approval.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-paroxysmal-nocturnal-hemoglobinuria-a-rare-disease-catalyst\">Paroxysmal Nocturnal Hemoglobinuria: A Rare\u2011Disease Catalyst<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PNH<\/strong> is an acquired, lifelong hemolytic disorder driven by uncontrolled complement activation due to deficiencies in <strong>CD55 (Decay Accelerating Factor)<\/strong> and <strong>CD59 (Membrane Inhibitor of Reactive Lysis)<\/strong>.<\/li>\n\n\n\n<li>Clinical hallmarks include <strong>intravascular hemolysis<\/strong>, progressive <strong>hematopoietic failure<\/strong>, and a heightened propensity for <strong>thrombosis<\/strong>.<\/li>\n\n\n\n<li>Because of its low prevalence, PNH appears on China\u2019s <strong>First National List of Rare Diseases<\/strong>, ensuring eligibility for expedited regulatory pathways and special reimbursement schemes.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-implications-for-jiangsu-hengrui\">Implications for Jiangsu Hengrui<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Potential<\/strong> \u2013 The PNH market in China is modest (estimated 5,000\u20136,000 patients nationwide), yet the disease\u2019s inclusion on the national rare\u2011disease list unlocks <strong>special pricing<\/strong> and <strong>accelerated market access<\/strong> once approval is granted.<\/li>\n\n\n\n<li><strong>Regulatory Momentum<\/strong> \u2013 Priority Review typically shortens the post\u2011approval review period by 6\u201312\u202fmonths; Hengrui is now poised to move from a fast\u2011track investigational product to an approved therapy much sooner than the standard 12\u2011month timeline.<\/li>\n\n\n\n<li><strong>Strategic Positioning<\/strong> \u2013 With the single existing complement\u2011inhibitor (iptacopan) approved only abroad, HRS\u20115965 could capture a sizeable share of the domestic rare\u2011disease market and serve as a launchpad for future complement\u2011inhibitor indications (e.g., atypical hemolytic uremic syndrome, myasthenia gravis).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\">Conclusion<\/h2>\n\n\n\n<p>Jiangsu Hengrui\u2019s receipt of <strong>Priority Review<\/strong> for HRS\u20115965 underscores the <strong>NMPA\u2019s commitment<\/strong> to fast\u2011tracking therapies for <strong>rare diseases<\/strong> while simultaneously advancing the company\u2019s portfolio against a backdrop of <strong>complement\u2011inhibitor expansion<\/strong>. The next fiscal quarter will be pivotal as bridging studies in China move to confirm efficacy and safety in the target PNH cohort.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600276_20251104_AZN3.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20251104_AZN3.\"><\/object><a id=\"wp-block-file--media-d3957bde-6ecb-4550-96ce-5c2c1620f35a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600276_20251104_AZN3.pdf\">600276_20251104_AZN3<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600276_20251104_AZN3.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d3957bde-6ecb-4550-96ce-5c2c1620f35a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45922,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4228,24,852],"class_list":["post-45919","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-1276","tag-rare-orphan-disease-drugs","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Hengrui Secures Priority Review for HRS\u20115965 in China\u2019s Rare\u2011Disease Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA) has granted Priority Review status to its investigational HRS\u20115965 capsule, targeting adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not yet received complement\u2011inhibitor therapy.The decision positions HRS\u20115965 as a potential first\u2011in\u2011class complement factor\u202fB inhibitor in the rapidly evolving PNH market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45919\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Hengrui Secures Priority Review for HRS\u20115965 in China\u2019s Rare\u2011Disease Portfolio\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA) has granted Priority Review status to its investigational HRS\u20115965 capsule, targeting adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not yet received complement\u2011inhibitor therapy.The decision positions HRS\u20115965 as a potential first\u2011in\u2011class complement factor\u202fB inhibitor in the rapidly evolving PNH market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45919\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T14:36:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-05T14:36:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45919#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45919\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Hengrui Secures Priority Review for HRS\u20115965 in China\u2019s Rare\u2011Disease Portfolio\",\"datePublished\":\"2025-11-05T14:36:14+00:00\",\"dateModified\":\"2025-11-05T14:36:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45919\"},\"wordCount\":428,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45919#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0506-1.webp\",\"keywords\":[\"HKG: 1276\",\"Rare \\\/ orphan disease drugs\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45919#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45919\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45919\",\"name\":\"Jiangsu Hengrui Secures Priority Review for HRS\u20115965 in China\u2019s Rare\u2011Disease Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45919#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45919#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0506-1.webp\",\"datePublished\":\"2025-11-05T14:36:14+00:00\",\"dateModified\":\"2025-11-05T14:36:16+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA) has granted Priority Review status to its investigational HRS\u20115965 capsule, targeting adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not yet received complement\u2011inhibitor therapy.The decision positions HRS\u20115965 as a potential first\u2011in\u2011class complement factor\u202fB inhibitor in the rapidly evolving PNH market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45919#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45919\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45919#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0506-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0506-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jiangsu Hengrui Secures Priority Review for HRS\u20115965 in China\u2019s Rare\u2011Disease Portfolio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45919#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Hengrui Secures Priority Review for HRS\u20115965 in China\u2019s Rare\u2011Disease Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Hengrui Secures Priority Review for HRS\u20115965 in China\u2019s Rare\u2011Disease Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA) has granted Priority Review status to its investigational HRS\u20115965 capsule, targeting adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not yet received complement\u2011inhibitor therapy.The decision positions HRS\u20115965 as a potential first\u2011in\u2011class complement factor\u202fB inhibitor in the rapidly evolving PNH market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45919","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Hengrui Secures Priority Review for HRS\u20115965 in China\u2019s Rare\u2011Disease Portfolio","og_description":"Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA) has granted Priority Review status to its investigational HRS\u20115965 capsule, targeting adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not yet received complement\u2011inhibitor therapy.The decision positions HRS\u20115965 as a potential first\u2011in\u2011class complement factor\u202fB inhibitor in the rapidly evolving PNH market.","og_url":"https:\/\/flcube.com\/?p=45919","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-05T14:36:14+00:00","article_modified_time":"2025-11-05T14:36:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45919#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45919"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Hengrui Secures Priority Review for HRS\u20115965 in China\u2019s Rare\u2011Disease Portfolio","datePublished":"2025-11-05T14:36:14+00:00","dateModified":"2025-11-05T14:36:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45919"},"wordCount":428,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45919#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506-1.webp","keywords":["HKG: 1276","Rare \/ orphan disease drugs","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45919#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45919","url":"https:\/\/flcube.com\/?p=45919","name":"Jiangsu Hengrui Secures Priority Review for HRS\u20115965 in China\u2019s Rare\u2011Disease Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45919#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45919#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506-1.webp","datePublished":"2025-11-05T14:36:14+00:00","dateModified":"2025-11-05T14:36:16+00:00","description":"Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA) has granted Priority Review status to its investigational HRS\u20115965 capsule, targeting adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not yet received complement\u2011inhibitor therapy.The decision positions HRS\u20115965 as a potential first\u2011in\u2011class complement factor\u202fB inhibitor in the rapidly evolving PNH market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45919#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45919"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45919#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506-1.webp","width":1080,"height":608,"caption":"Jiangsu Hengrui Secures Priority Review for HRS\u20115965 in China\u2019s Rare\u2011Disease Portfolio"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45919#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Hengrui Secures Priority Review for HRS\u20115965 in China\u2019s Rare\u2011Disease Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45919"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45919\/revisions"}],"predecessor-version":[{"id":45923,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45919\/revisions\/45923"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45922"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}